ContraVir Pharmaceuticals to Provide Corporate, Business and Clinical Updates
Conference Call Information:
Interested participants and investors may access the conference call by dialing 1 (409) 983-9733 or 1 (844) 535-3939 and providing audience code 1042879.
An audio webcast will be accessible via the Investors section of ContraVir’s website at http://ir.contravir.com/investor-relations. An archive of the webcast will remain available for 90 days beginning at approximately
ContraVir is a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies with a specific focus on developing a potentially curative therapy for hepatitis B virus (HBV). The company is developing two novel anti-HBV compounds with complementary mechanisms of action. TXL™, a nucleoside analog lipid prodrug of tenofovir (TFV), is designed to deliver higher hepatic intracellular concentrations of the active tenofovir species (tenofovir diphosphate) while reducing concentrations of tenofovir outside the liver, causing fewer off-target toxicities and side-effects. CRV431, the other anti-HBV compound, is a next-generation cyclophilin inhibitor with a novel structure that increases its potency and selective index against HBV. In vitro and in vivo studies have thus far demonstrated that CRV431 reduces HBV DNA and other viral proteins, including surface antigen (HBsAg). For more information visit www.contravir.com.
For further information, please contact:
Director of Investor Relations
email@example.com; (732) 902-4028
Source: ContraVir Pharmaceuticals Inc.